Company Overview and News

0
Nestle India market cap crosses Rs 1 lakh cr

1h moneycontrol
FMCG major Nestle India's market valuation has surged past Rs 1 lakh crore mark helped by a rally in its share price. The company's market valuation stood at Rs 1,01,541.66 crore at close of trade on BSE today.
500696 NESTLEIND HINDUNILVR NSZTY 500790

0
An evening walk down Dalal Street | Sensex up almost 200 pts, Nifty back at 11,000

5h moneycontrol
After starting the week on a negative note, the market on Tuesday looked to reclaim its positive momentum from last week, backed by sharp gains in midcaps. The Sensex managed to end the day almost 200 points higher, while the Nifty managed to end above 11,000-mark.
IOC 500469 532617 TCHQY HINDUNILVR FEDA 532755 532187 532461 FEDS 500696 500477 FEDERALBNK ASHOKLEY SBAZ INDIGO INDUSINDBK JETAIRWAYS FDBAY 530965 AKLD TECHM 539448 PNJZY PNB AKLS

0
HUL profit rises 19% to Rs 1,529 cr in Q1

10h freepressjournal.in
Mumbai : FMCG major Hindustan Unilever on Monday reported a 19.17 per cent increase in standalone net profit at Rs 1,529 crore for the first quarter ended June 30, 2018 despite a rise in materials.
500696 HINDUNILVR

4
Sensex rises over 100 points after sharp fall in crude prices

10h freepressjournal.in
Mumbai: The BSE Sensex recovered over 107 points to 36,431.17 in early trade today on fresh buying by investors after a sharp drop on global crude oil prices and a strengthening rupee.
YESBANK IBN HINDUNILVR 532648 YYBKY VEDL ICICIBANK 500470 TTST TATASTEEL TATLY 532174 500696 500570 TATAMOTORS TTM

0
HUL slips 3% despite a better Q1 show; brokerages downgrade rating but raise target price

11h moneycontrol
Shares of Hindustan Unilever slipped more than 3 percent intraday Tuesday despite company reporting better numbers in the quarter ended June 2018. The share has touched a 52-week high of Rs 1,779.95 during the opening trade. The company had reported a 19.2 percent YoY rise in its standalone net profit to Rs 1,529 crore for the quarter ended June.
MS.PRI MS.PRK MS.PRE 500696 MS.PRF HINDUNILVR MS.PRG MS MS.PRA

0
HUL posts biggest intraday fall in 11 weeks

11h thehindubusinessline
Shares of consumer goods maker Hindustan Unilever Ltd fell as much as 2.9 per cent to Rs 1,701 rupees, in its biggest intraday percentage fall since May 2, as the company’s net profit missed street estimates.
MS.PRI MS.PRK MS.PRE 500696 MS.PRF HINDUNILVR MS.PRG MS MS.PRA

5
Sensex falls 218 pts, Nifty below 11k as WPI inflation races to 4-yr high

2018-07-16 freepressjournal.in
Mumbai: The benchmark BSE Sensex dropped by around 218 points or 0.60 per cent due to sell-off in banking, pharma, and metal stocks as investors turned cautious after wholesale inflation surged to a four-year high. The broad-based Nifty cracked below the 11,000-mark as 35 of its constituents closed in the red, led by Dr Reddy’s, Tata Steel and Lupin.
IBN HINDUNILVR BHRQY 533278 VEDL 532454 ICICIBANK 500470 TTST TATASTEEL TATLY HDB 532174 500180 500696 HDFCBANK 500570 BHARTIARTL TATAMOTORS CLNDY COALINDIA TTM

0
HUL Q1 net profit rises 19% to Rs 1,529 core

2018-07-16 livemint
New Delhi: FMCG major Hindustan Unilever Ltd (HUL) on Monday reported a 19.17% increase in standalone net profit at Rs 1,529 crore for the first quarter ended June 30, 2018. The company had posted a net profit of Rs 1,283 crore in the same period of the previous fiscal.
500696 HINDUNILVR

0
Hindustan Unilever Limited - Investor Presentation

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500696 HINDUNILVR

0
Hindustan Unilever Limited - Financial Result Updates

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500696 HINDUNILVR

0
HUL Q1 net profit rises 19.2% YoY to Rs 1,529 crore

2018-07-16 moneycontrol
Hindustan Unilever, India's biggest consumer goods company, on Monday reported a 19.2 percent YoY rise in its standalone net profit to Rs 1,529 crore for the quarter ended June.
500696 HINDUNILVR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...